IP Library › Patent Application 15960041
Patent Application
App. No. 15/960,041

DEUTERATED ANALOGS OF PRIDOPIDINE USEFUL AS DOPAMINERGIC STABILIZERS

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
15/960,041
Abstract

The present invention provides novel deuterated analogs of Pridopidine, i.e. 4-(3-methanesulfonyl-phenyl)-1-propyl-piperidine. Pridopidine is a drug substance currently in clinical development for the treatment of Huntington's disease. In other aspects the invention relates to pharmaceutical compositions comprising a deuterated analog of Pridopidine of the invention, and to therapeutic applications of these analogs.

Claims (26)

1 . A fully or partially deuterated analog of 4-(3-methanesulfonyl-phenyl)-1-propyl-piperidine represented by Formula 1

or a pharmaceutically acceptable salt thereof, wherein

at least one of R 1 -R 23 represents deuterium (D); and

the remaining of R 1 -R 23 represent hydrogen (H).

2 . The deuterated analog according to claim 1 , or a pharmaceutically acceptable salt thereof, wherein

R 1 -R 2 represent deuterium (D); and

all of R 3 -R 23 represent hydrogen (H).

3 . The deuterated analog according to claim 1 , or a pharmaceutically acceptable salt thereof, wherein

at least one of R 1 -R 7 represents deuterium (D); and

the remaining of R 1 -R 23 represent hydrogen (H).

4 . The deuterated analog according to claim 1 , or a pharmaceutically acceptable salt thereof, wherein

all of R 1 -R 7 represent deuterium (D); and

all of R 8 -R 23 represent hydrogen (H).

5 . The deuterated analog according to claim 1 , or a pharmaceutically acceptable salt thereof, wherein

R 8 , R 9 , R 10 and R 11 represent deuterium (D); and

all of R 1 -R 7 and R 12 -R 23 represent hydrogen (H).

6 . The deuterated analog according to claim 1 , or a pharmaceutically acceptable salt thereof, wherein

R 12 represents deuterium (D); and

all of R 1 -R 11 and R 13 -R 23 represent hydrogen (H).

7 . The deuterated analog according to claim 1 , or a pharmaceutically acceptable salt thereof, wherein

R 17 -R 20 represent deuterium (D); and

all of R 1 -R 16 and R 21 -R 23 represent hydrogen (H).

8 . A pharmaceutical composition, comprising a therapeutically effective amount of a deuterated analog of 4-(3-methanesulfonyl-phenyl)-1-propyl-piperidine according to any one of claims 1 - 7 , or a pharmaceutically acceptable salt thereof, together with at least one pharmaceutically acceptable carrier, excipient or diluent.

9 . The deuterated analog of 4-(3-methanesulfonyl-phenyl)-1-propyl-piperidine according to any one of claims 1 - 7 , or a pharmaceutically acceptable salt thereof, for use as a medicament.

10 . Use of the deuterated analog according to any one of claims 1 - 7 , or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament.

11 . A method for treatment, prevention or alleviation of a dopamine mediated disorder of a living animal body, including a human, which method comprises the step of administering to such a living animal body in need thereof a therapeutically effective amount of a deuterated analog of 4-(3-methanesulfonyl-phenyl)-1-propyl-piperidine according to any one of the claims 1 - 7 , or a pharmaceutically acceptable salt thereof.